← The Wire
CGONNasdaq
CG Oncology, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1991792
Develops and commercializes cretostimogene grenadenorepvec, an immunotherapy for bladder cancer
red 8-K · 90d
$5.25B
Market cap
$73.73
Last close
+2.5%
1D
+11.3%
5D
1.1M
Volume
Price · last 39 sessions+8.9%
May 4L $53.72 · H $74.00Jun 29
58
Total filings
Jun 8, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 8, 20268-KExecutive ChangeMay 26, 202610-Q10-QMay 8, 20268-KResults of OperationsMay 8, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 20268-KExecutive ChangeApr 13, 202610-K10-KFeb 27, 20268-KResults of OperationsFeb 27, 20268-KCompany UpdateJan 13, 2026424B5424B5Jan 13, 20268-KReg FD Disclosure · Company UpdateJan 9, 20268-KExecutive ChangeNov 26, 20258-KExecutive ChangeNov 14, 202510-Q10-QNov 14, 20258-KResults of OperationsNov 14, 20258-KReg FD DisclosureSep 9, 20258-KReg FD Disclosure · Company UpdateSep 5, 202510-Q10-QAug 8, 20258-KResults of OperationsAug 8, 20258-KExecutive ChangeJul 11, 20258-KShareholder VoteJun 6, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 20258-KReg FD Disclosure · Company UpdateApr 28, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 202510-K10-KMar 28, 20258-KResults of OperationsMar 28, 20258-KReg FD Disclosure · Company UpdateMar 24, 20258-KExecutive ChangeJan 10, 2025424B4424B4Dec 13, 2024S-1/AS-1/ADec 11, 2024S-1S-1Dec 11, 20248-KReg FD Disclosure · Company UpdateDec 5, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 22, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 2024SC 13GSC 13GJul 22, 20248-KReg FD Disclosure · Company UpdateMay 24, 20248-KResults of OperationsMay 9, 202410-Q10-QMay 9, 20248-KCompany UpdateMay 3, 202410-K10-KMar 26, 2024SC 13GSC 13GMar 14, 20248-KExecutive ChangeFeb 16, 2024SC 13GSC 13GFeb 9, 2024SC 13GSC 13GFeb 8, 2024SC 13GSC 13GFeb 5, 2024SC 13GSC 13GFeb 5, 20248-KBylaw Amendment · Company UpdateJan 30, 2024424B4424B4Jan 25, 2024S-1/AS-1/AJan 23, 2024S-1/AS-1/AJan 18, 2024S-1S-1Jan 2, 2024
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $710K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Mulay JamesDirector | Sell | 1,310 | $63.50 | $83K |
| Mar 16, 2026 | Mulay JamesDirector | Sell | 654 | $63.50 | $42K |
| Jan 9, 2026 | Mulay JamesDirector | Sell | 10,491 | $52.99 | $556K |
| Jan 9, 2026 | Mulay JamesDirector | Sell | 654 | $44.16 | $29K |
| Nov 17, 2025 | Post Leonard EDirector | Sell | 1,000 | $41.43 | $41K |
| Oct 13, 2025 | Post Leonard EDirector | Sell | 1,000 | $43.25 | $43K |
| Oct 9, 2025 | Mulay JamesDirector | Sell | 5,903 | $43.99 | $260K |
| Sep 30, 2025 | Post Leonard EDirector | Sell | 5,000 | $40.09 | $200K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance